pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›TOLVAPTAN
drug
save

TOLVAPTAN

Marketedupdated 6mo ago
by Otsuka America Pharmaceutical Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval2 co-mentions · 1 sources
  • drugSamsca1 co-mentions · 1 sources
  • tagSmall Molecule1 co-mentions · 1 sources

all catalysts(1)

approval · 1
Nov 10, 2025
approval
1y ago
TOLVAPTAN — FDA approval
TOLVAPTAN
→

Trials studying TOLVAPTAN

  • phase3A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)recruitingn=20
  • phase3A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)withdrawn
  • —Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKDcompletedn=1,802
  • phase1A Study of HRS-9057 in Patients With Heart Failure and Volume Overloadcompletedn=25
  • phase1Phase I Study Multi Dose of 7.5mg Tolvaptan in Health Malecompletedn=12
  • phase1Single Dose of 7.5mg Tolvaptan Phase I Clinical Trial Protocolcompletedn=10
  • —Samsca PMS in ADPKD Patientscompletedn=2,067
  • phase2A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremiacompletedn=241

Patent cliff

source: FDA Orange Book
first barrier falls
Apr 7, 2030
~3.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (16)

  • Apr 7, 2030formulationUS 109056943.4y
  • Apr 7, 2030formulationUS 109056943.4y
  • Apr 7, 2030formulationUS 109056943.4y
  • Apr 7, 2030formulationUS 109056943.4y
  • Apr 7, 2030formulationUS 109056943.4y
  • Apr 7, 2030formulationUS 109056943.4y
  • Apr 7, 2030formulationUS 109056943.4y
  • Apr 7, 2030formulationUS 109056943.4y
  • Sep 1, 2026compositionUS 8501730
  • Sep 1, 2026compositionUS 8501730
  • Sep 1, 2026compositionUS 8501730
  • Sep 1, 2026compositionUS 8501730
  • Sep 1, 2026compositionUS 8501730
  • Sep 1, 2026compositionUS 8501730
  • Sep 1, 2026compositionUS 8501730
  • Sep 1, 2026compositionUS 8501730

News(2)

  • Biogen-backed Estuary nabs $93M for kidney disease gene therapy
    The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as "ADPKD."
    biopharma_dive · 1mo ago
  • Estuary flows out of stealth with $103M to propel kidney disease gene therapies into clinic
    Estuary Biotherapeutics has swum out of stealth with $103 million in funding to power a pair of gene therapies into clinical trials for an inherited kidney disorder.
    fiercebiotech · 1mo ago
brand
TOLVAPTAN
generic
TOLVAPTAN
indication
Polycystic Kidney Disease
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?